Systemic @entity3446 to prevent in-stent @entity850 in XXXX : early clinical experience.

@entity1 @entity4065 @entity101 @entity3657 @entity67 @entity8404 @entity215 @entity294 @entity120 @entity3446 @entity850 @entity204 @entity360
OBJECTIVES: We have taken a novel approach using oral @entity3446 - @entity3446 - as a medical adjunct to percutaneous therapy in @entity1 with in-stent @entity850 and high risk of @entity67 . BACKGROUND: @entity3657 can result in @entity101 , dysfunction, and @entity204 . Percutaneous pulmonary artery angioplasty and stent placement acutely relieve obstructions, but @entity1 frequently require re-interventions due to @entity850 . In @entity1 with tetralogy of @entity215 or @entity4065 , the problem of in-stent @entity850 contributes to the rapidly recurrent disease. METHODS: @entity3446 was administered to 10 @entity1 (1.5-18 years) with @entity8404 and in-stent @entity850 and either @entity101 , pulmonary blood flow maldistribution, or @entity120 . Treatment was initiated around the time of catheterisation and continued for 1-3 months. Potential side-effects were monitored by clinical review and blood tests. RESULTS: Target serum @entity3446 level (6-10 ng/ml) was accomplished in all @entity1 ; eight of the nine @entity1 who returned for clinically indicated catheterisations demonstrated reduction in in-stent @entity850 , and eight of the 10 @entity1 experienced no significant side-effects. Among all, one @entity1 developed @entity294 requiring drug discontinuation, and one @entity1 experienced @entity360 while on therapy that was likely due to an indwelling feeding tube and this @entity1 tolerated @entity3446 well following tube removal. CONCLUSIONS: Our initial clinical experience supports that @entity1 with @entity3657 can be safely treated with @entity3446 . Systemic @entity3446 may provide a novel medical approach to reduce in-stent @entity850 .
